Human cystathionine β-synthase variants and methods of production thereof
Human cystathionine β-synthase variants are disclosed, as well as a method to produce recombinant human cystathionine β-synthase and variants thereof. More particularly, the role of both the N-terminal and C-terminal regions of human CBS has been studied, and a variety of truncation mutants and modified CBS homologues are described. In addition, a method to express and purify recombinant human cystathionine β-synthase (CBS) and variants thereof which have only one or two additional amino acid residues at the N-terminus are described.
1. A truncated form of human cystathionine β-synthase (CBS) protein having human cystathionine β-synthase biological activity, said protein having:
(i) an amino acid sequence that is at least 95% identical to amino acid sequence spanning from a starting position of amino acid residue 1 or one of amino acid residues from 66-84 of SEQ ID NO:2 to an ending position of one of amino acid residues from 382-532 or 543-550 of SEQ ID NO:2; and
(ii) having no more than 2 non-human, non-CBS amino acid residues at the N-terminus.
2. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that spans from a starting position of amino acid residue 1 of SEQ ID NO:2.
3. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that spans from a starting position of one of amino acid residues from 66-84 of SEQ ID NO:2.
4. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that spans from a starting position of one of amino acid residues from 66-71 of SEQ ID NO:2.
5. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that spans from a starting position of one of amino acid residues from 70-84 of SEQ ID NO:2.
6. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that spans from a starting position of one of amino acid residues from 70 or 71 of SEQ ID NO:2.
7. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that ends at a position of one of amino acid residues from 382-532 and having no more than 2 non-human, non-CBS amino acid residues at the N-terminus.
8. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that ends at a position of one of amino acid residues from 543-550 and having no more than 2 non-human, non-CBS amino acid residues at the N-terminus.
9. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that ends at a position of one of amino acid residues from 400-523 and having no more than 2 non-human, non-CBS amino acid residues at the N-terminus.
10. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that ends at a position of one of amino acid residues from 488-523 and having no more than 2 non-human, non-CBS amino acid residues at the N-terminus.
11. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein has an amino acid sequence that ends at a position of one of amino acid residues from 496-523 and having no more than 2 non-human, non-CBS amino acid residues at the N-terminus.
12. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein does not bind heme.
13. The truncated form of human cystathionine β-synthase protein of claim 1 , wherein said protein contain at its N-terminus the two C-terminal amino acid residues of the rhinovirus 3C protease recognition site.
14. A method for treating homocystinuria, comprising administering to a patient a truncated form of human cystathionine β-synthase protein having:
(i) an amino acid sequence that is at least 95% identical to amino acid sequence spanning from a starting position of amino acid residue 1 or one of amino acid residues from 66-84 of SEQ ID NO:2 to an ending position of one of amino acid residues from 382-532 or 543-550 of SEQ ID NO:2; and
(ii) having no more than 2 non-human, non-CBS amino acid residues at the N-terminus.
15. The truncated form of human cystathionine β-synthase (CBS) of any of claims 1 - 13 that is substantially purified.
16. A composition comprising the truncated form of human cystathionine β-synthase (CBS) of claim 15 , and a pharmaceutically acceptable carrier.